glp-1/gip agonists Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Effects, working principles and target

E., Battaglia F., Hen R

Weight loss is a complex medical process that should always involve professional guidance

On the other hand, gastric emptying is not considerably impacted by glucose-dependent insulinotropic polypeptide (GIP), emphasizing the distinct functions of these incretins in GI function ( A study examined the potential advantages and disadvantages of using GLP-1RAs to help obese but non-diabetic patients lose weight

This study aims to explore this gap by utilizing data from the large community-based database, TriNetX, to investigate the association between GLP-1 RA use and the risk of psychiatric diseases, including major depression, anxiety and suicidal behaviour in patients with obesity

Pediatric and Adolescent Obesity Treatment: Since FDA approval in 2022, GLP-1 receptor agonists have been prescribed for individuals aged 12 years and older with obesity (BMI 95th percentile)